268 A phase 1 study of retifanlimab (INCMGA00012), a PD-1 inhibitor, in patients with advanced solid tumors: preliminary results in recurrent MSI-high or dMMR endometrial cancer (POD1UM-101)

• Ignace Vergote,
• Frédéric Selle,
• Dominique Berton-Rigaud,
• Patricia Pautier,
• Chuan Tian,
• Anna Kryzhanivska,
• Antoine Angelergues,
• Deanna Kornacki,
• Monika Dudzisz-Sledz,
• Nawel Bourayou

Affiliations

Ignace Vergote

2UZ Leuven, Leuven, Belgium

Frédéric Selle

5Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France

Dominique Berton-Rigaud

1Institut de Cancérologie de l’Ouest, Saint-Herblain, France

Patricia Pautier

3Gustave-Roussy, Villejuif, France

Chuan Tian

Incyte Corporation, Wilmington, DE, USA

Anna Kryzhanivska

4Regional Clinical Oncology Center, Ivano-Frankivsk, Ukraine

Antoine Angelergues

5Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France

Deanna Kornacki

6Incyte Corporation, Wilmington, DE, USA

Monika Dudzisz-Sledz

7KCR S.A.; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

Nawel Bourayou

6Incyte Corporation, Wilmington, DE, USA